Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Sareum Hldgs Plc
SARSareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases. Its also developing SDC-1802, a TYK2/JAK1 inhibitor, which is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom. Address: Langford Arch, Cambridge, United Kingdom, CB22 3FX
Analytics
Objectif de Cours de WallStreet
138.96 GBPRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés SAR
Analyse des dividendes SAR
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes SAR
Valorisation des titres SAR
financières SAR
Résultats | 2019 | Dynamique |